Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $190.25.

A number of brokerages recently commented on RGEN. Wells Fargo & Company assumed coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Benchmark reaffirmed a “hold” rating on shares of Repligen in a research note on Monday, August 5th.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Institutional investors have recently added to or reduced their stakes in the company. O Shaughnessy Asset Management LLC lifted its stake in shares of Repligen by 6.9% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 1,924 shares of the biotechnology company’s stock valued at $354,000 after purchasing an additional 125 shares in the last quarter. UniSuper Management Pty Ltd grew its stake in Repligen by 100.0% during the first quarter. UniSuper Management Pty Ltd now owns 800 shares of the biotechnology company’s stock worth $147,000 after buying an additional 400 shares during the period. CANADA LIFE ASSURANCE Co increased its position in shares of Repligen by 1.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 38,559 shares of the biotechnology company’s stock worth $7,086,000 after acquiring an additional 567 shares in the last quarter. Advisors Asset Management Inc. raised its stake in shares of Repligen by 21.6% in the 1st quarter. Advisors Asset Management Inc. now owns 13,827 shares of the biotechnology company’s stock valued at $2,543,000 after acquiring an additional 2,456 shares during the period. Finally, Lazard Asset Management LLC lifted its holdings in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 136 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 0.4 %

Shares of Repligen stock opened at $150.54 on Friday. The company has a 50-day moving average of $140.98 and a two-hundred day moving average of $142.85. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.43 billion, a PE ratio of -406.86, a price-to-earnings-growth ratio of 4.52 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.23 earnings per share. On average, research analysts anticipate that Repligen will post 1.52 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.